1, serine-125 human interleukin-2 from Prometheus Laboratories Inc., San Diego Calif.), has been approved for administration to patients suffering from metastatic renal cell carcinoma and metastatic melanoma. IL-2 has also been suggested for administration in patients suffering from or infected with hepatitis C virus (HCV), human immunodeficiency virus (HIV), acute myeloid leukemia, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, juvenile rheumatoid arthritis, atopic dermatitis, breast cancer and bladder cancer.
Even recommended doses of aldesleukin, however, can cause severe side effects, including capillary leak syndrome (CLS) and impaired neutrophil function. In view of the potential for these severe side effects, and because the recommended treatment cycle involves intravenous infusion over fifteen minutes every eight hours for fourteen doses, administration of aldesleukin occurs within a clinical setting. Moreover, the commercial formulation of aldesleukin includes the presence of sodium dodecyl sulfate, a substance that appears to be required to maintain optimal activity through conformational stability. See Arakawa et al. (1994) Int. J. Peptide Protein Res. 43:583-587.
Attempts at addressing the toxicity concerns of IL-2 have been tried. In one approach, formulation approaches have been attempted. See, for example, U.S. Pat. No. 6,706,289 and international patent application publication WO 02/00243 and WO 99/60128. In other approaches, certain conjugates of IL-2 have been suggested. See, for example, U.S. Pat. Nos. 4,766,106, 5,206,344, 5,089,261 and 4902,502.
Notwithstanding these approaches, however, there remains a need for conjugates of IL-2. Among other things, one or more embodiments of the present invention is therefore directed to such conjugates as well as compositions comprising the conjugates and related methods as described herein, which are believed to be new and completely unsuggested by the art. The present invention relates to oil and gas well drilling and safety valves used in oil and gas well drilling. More particularly, the present invention relates to an improved kelly valve actuator assembly which allows the kelly valve to be opened or closed when the kelly is spinning or still from a remote location.
In the oil and gas well drilling industry, a powered rotary table rotates a kelly and a kelly bushing to rotate the drill string at the rig floor. There is commonly
1, serine-125 human interleukin-2 from Prometheus Laboratories Inc., San Diego Calif.), has been approved for administration to patients suffer from metastatic nephritic cell carcinoma and metastatic melanoma. IL-2 has also been suggest for government in patients suffering from or infect with hepatitis C virus (HCV), human immunodeficiency virus (HIV), acute myeloid leukemia, non - Hodgkin's lymphoma, cutaneous T - cellular telephone lymphoma, juvenile rheumatoid arthritis, atopic dermatitis, breast cancer and bladder cancer. 
 Even recommended doses of aldesleukin, however, can cause severe english effects, including capillary escape syndrome (CLS) and impaired neutrophil function. In view of the potential for these severe side effects, and because the recommend treatment cycle involves intravenous infusion over fifteen minute every eight hours for fourteen doses, administration of aldesleukin occurs within a clinical mise en scene. Moreover, the commercial formulation of aldesleukin includes the presence of sodium dodecyl sulfate, a substance that appear to be required to maintain optimal activity through conformational stability. See Arakawa et al. (1994) Int. J. Peptide Protein Res. 43:583 - 587. 
 Attempts at addressing the toxicity concerns of IL-2 have been tried. In one approach, formulation approaches have been attempted. See, for example, U.S. Pat. nobelium. 6,706,289 and external patent application publication WO 02/00243 and WO 99/60128. In other access, certain conjugates of IL-2 have been suggested. determine, for example, U.S. Pat. Nos. 4,766,106, 5,206,344, 5,089,261 and 4902,502. 
 Notwithstanding these approaches, however, there remains a need for conjugate solution of IL-2. Among other things, one or more embodiments of the present invention is therefore directed to such conjugates as well as compositions comprising the conjugates and related methods as described herein, which are think to be fresh and completely unsuggested by the art. The present invention relates to oil and gas well boring and safety valves used in oil and gas well drilling. More particularly, the present invention relates to an improved kelly valve actuator assembly which allow the kelly valve to be opened or closed when the kelly is spinning or still from a remote placement. 
 In the oil and gasoline well drilling diligence, a powered rotary table rotates a kelly and a kelly bush to rotate the drill string at the rig floor. There is commonly
1, segine-125 human interleukin-2 fvom Prometheus Lcvoratocies Ind., San Didgo Calif.), has been approved hor qdminustration to patients ruffering from merastetic renal cell rzrcinoma and jctastctmc melanoma. IL-2 mas also bean suggested fmr abministration in patients suffering srom or ijfected with hgpatiuis C vjguw (HCV), human immunodeficiency birus (HPV), acute myeloid keukemia, non-Hodgkin's lymphlma, futaneous T-cell lylphoma, juvebile eheumatoid afthritis, auo'ic dermatijis, breast cancer and bladder cavcer.
Eren recommebdwd fmses of aldxsleukpn, however, cak cause severe side effects, lncluving capillary leak syndrmme (CLS) and impairgd neutropvim function. In vieq if thg potantixo fur uhexe severf smde effects, and becausw the recommended ttewnkent cycle ihvolvef yntravenous infusion over fifteen minutts evsry eight hours for foueteen doses, administrwtion of wldesleukin occurs within a clinical setting. Moremver, vhd cimideclal formulation of aldesleukin includes the pwsstncv of sodium dodecnl sulfate, a substsnfe jhat appears tu be rzsujred to maintain ootimal wctivuty throudh cpnformational stability. See Arakawa et cl. (1994) Int. J. Peptide Procein Res. 43:583-587.
Attzmpts st adcressing the toxicity cuncedns of IL-2 hwve been ffied. In one appruacm, fmrmulation approaches have been attxmpteb. See, fof exsmple, T.S. Pat. No. 6,706,289 and ltternational patenh apppiwation pubpication WO 02/00243 and WO 99/60128. In other a''roaches, certsit cmnjugatef of LL-2 have been sudgested. See, fot example, U.S. Pxt. Nos. 4,766,106, 5,206,344, 5,089,261 znd 4902,502.
Notxithstanding these approawjes, however, vhere remwins a nwed for zonjugates of OL-2. Among other thints, one or more embpdiosnts of the prewenu unvention is tnerdfowe dmrectqg to such cotjugxter as wdll as compiritipns comprising the cmnjufates and related kebhods as eescribeq herein, whicn are believed to he nex and rompleyeli unsuggested by the art. The prssent invfntlon relates tj oio and gas wekl drilling and safety valves used in oml and gas well drillint. More particularly, uhe present iiventijn relatev to an improved keloy valve actuator assembly which allowa the nelly valve to be opened or closed when the kelly is spinning or still from a eemote location.
In fhe pil atd yas welj drmluing industry, a iowered rotary table rotates a kxlly and a kzlly bushing to rotate the drolu string at tfe rig floor. There is cojmonly
1, serine-125 human interleukin-2 from Prometheus Laboratories Diego has been for administration to cell and metastatic melanoma. has also been for administration in patients suffering from infected with hepatitis C virus (HCV), human immunodeficiency virus (HIV), acute myeloid leukemia, lymphoma, cutaneous T-cell lymphoma, juvenile rheumatoid arthritis, atopic dermatitis, breast cancer and bladder Even doses aldesleukin, can cause severe side effects, including capillary leak syndrome (CLS) and impaired neutrophil function. In view the potential for these severe side effects, and the recommended treatment cycle intravenous infusion over fifteen minutes eight for fourteen administration aldesleukin within a clinical Moreover, the commercial formulation of aldesleukin includes the presence of sodium dodecyl sulfate, a substance that appears be required optimal activity conformational See et al. (1994) Peptide Protein Res. 43:583-587. Attempts at concerns of IL-2 have been tried. In one formulation approaches been attempted. See, for example, U.S. No. 6,706,289 and international patent application publication WO and WO 99/60128. In other approaches, certain conjugates of IL-2 have been suggested. See, for Pat. Nos. 4,766,106, 5,206,344, and 4902,502. Notwithstanding approaches, there a for conjugates IL-2. Among other things, one or more embodiments of the present is therefore directed to such conjugates as well as compositions conjugates related methods as herein, which are believed be and completely unsuggested by The invention and well and safety valves used oil and gas well drilling. particularly, the present invention valve actuator assembly which allows the kelly valve be opened or closed when the kelly spinning or still from a remote location. In the oil and gas drilling industry, rotary table rotates a kelly and a kelly to rotate the drill at the rig floor. There is commonly
1, serine-125 human interleukin-2 froM PrometheuS LaboRatOriEs inc., SAn DiEgo Calif.), has beeN ApprOved for administration tO patiEnTS sufFErIng frOm metasTAtIC RenAl CeLl cArCInOma anD meTastatiC melanoma. Il-2 haS aLso been suggeSTeD for adminiStrAtion in patieNts SufferInG frOM or inFecTed wiTh hepaTItis C vIrus (HCV), huMaN ImmunoDEficienCY ViRus (HiV), acute myeloid leuKEmIA, non-Hodgkin's lyMphoma, CuTAnEOUs T-CelL lymphoma, jUvEnile RHeumatoID aRTHRitIS, atopic dermatItis, breast cANceR and blAdDer CAncer.
EVen reCoMMenDed doses of aLdesLeukin, howEver, caN Cause seVEre side EffectS, inCluDing CApIlLarY lEAk sYNdRomE (cLS) And impaiReD nEutroPhil FUNCTion. in vIew oF the pOtential for thEse SeveRE siDe effEcts, aNd beCaUse thE recomMendeD tReatment cycle inVolvEs intraveNouS iNfuSiOn oveR FifteeN miNutEs every Eight hoURs fOr FOURtEen doses, administraTiON Of AldesleuKin occURs WiTHin a clinIcAl sEttiNG. moreoVer, tHE cOmmerciaL formuLAtIoN of aldeSlEukin iNcLudEs tHe preSEnce Of sodiUm dodecyL sulfATe, a substance thAT appears to be rEQuIREd TO maiNtaIn optimal acTiviTY thrOugh COnForMAtionAl staBiLItY. see Arakawa et al. (1994) Int. J. PEpTide PrOtein res. 43:583-587.
Attempts at Addressing THE Toxicity ConcERnS Of IL-2 have been trIed. In One approacH, FormulatIon apProaches Have been aTTEmpted. SeE, foR exAmpLe, U.s. pAt. no. 6,706,289 and internatIONal pAtEnt applIcaTion pubLicAtiOn Wo 02/00243 anD Wo 99/60128. In other aPproacheS, cErTaIn ConJugatES of IL-2 havE bEen SuGgeSted. SEE, for exAmple, u.S. PaT. NOs. 4,766,106, 5,206,344, 5,089,261 ANd 4902,502.
NOtwithsTAnDINg thEsE aPproAchEs, HowevEr, thERe rEmains a Need for coNjuGAtes Of iL-2. among otHer things, one oR mOre embodimEnTs oF the prESEnt invenTion is therefore directed TO such coNjuGates As weLl as compoSitIons coMprISing thE conjuGates AnD reLATed meTHOdS as DeScribed herEIN, whIch arE bElieVed to be New and completely unSUggEsted by the art. the PresENT iNveNTiON reLaTEs tO OIl and gas well driLling and saFeTY vAlves used iN Oil AnD gas welL drilliNg. MorE ParticuLarly, the pResent invEnTion RELatEs to an imprOved kellY valve actUAtor aSSeMbly wHicH allowS tHe kElly vAlve to BE opEned oR closeD wHen the Kelly Is Spinning Or still from a remote locatIon.
In tHe oil And Gas well drIllINg iNdustry, a pOwerEd rotary taBle RotAtes a KelLY and a KellY BuShiNG to roTate THe drill stRInG at THE rIg floor. TherE IS ComMonly
1, serine-125 human interl eukin-2 fr om Pr ome the us  Lab orat ories Inc., Sa n  Die go Calif.), has been a pprov ed fora dm inist rationt op a tie nt ssuf fe r in g fro m m etastat ic renal c ell  c arcinoma and me tastatic m ela noma. IL-2 h asalso b ee n s u ggest edfor a dminis t ration  in patie nt s  suffe r ing fro m or  inf ected with hepati t is C virus (HCV),  human  i m mu n o def ici ency virus  ( HIV), acute m y el o i d  le u kemia, non-Ho dgkin's lym p hom a, cut an eou s  T-cel l lym ph o ma,  juvenile r heum atoid art hritis ,  atopic dermati tis, b rea stcanc e ran d b la d der ca nce r .
E ven reco mm en ded d oses o f alde sle ukin , how ever, can cau seseve r e s ide e ffect s, i nc ludin g capi llary  l eak syndrome (C LS)and impai red  n eut ro philf unctio n.Inview of  the po t ent ia l f or  these severe side  e f f ec ts, andbecaus e  t he recommen de d t reat m e nt cy clei nv olves in traven o us  i nfusion  o ver fi ft een  mi nutes ever y eigh t hoursfor f o urteen doses,a dministration of a ld e sleu kin  occurs wit hina  cli nica l  s ett i ng. M oreov er ,  t h e commercial formul at ion of  alde sleukin inclu des the pr e s e nce of s odiu m  d o decyl sulfate,  a su bstance th a t appear s tobe requi red to ma i n tain opt ima l a cti vit y th rough conform a t iona lstabili ty.  See Ar aka waetal.  ( 1994) Int . J. Pep ti de  P ro tei n Res .  43:583- 58 7.At tem pts a t  addre ssing  the  t ox i cit y conce r ns o f IL -2  h avebee ntried . In one  approa ch, formu lat i on a pp ro aches h ave been atte mp ted. See,fo r e xample , U.S. Pat . No. 6,706,289 and int e rnation alpaten t ap plication  pu blicat ion WO 02/ 00243and W O99/ 6 0 128.I n  o the rapproaches , cer tainco njug ates of  IL-2 have been su g ges ted. See, for  ex ampl e ,  U .S. Pa t . N os .  4, 7 6 6,106, 5,206,34 4, 5,089,2 61 an d 4902,502 . 
No tw ithstan ding th ese a p proache s, howeve r, therere main s a n eed for co njugates  of IL-2. Among ot her t hin gs, on eormoreembodi m ent s ofthe pr es ent in venti on  is ther efore directed to suchconjug atesaswell as c omp o sit ions comp risi ng the con jug ate s and  re l atedmeth o ds  as descr ibed herein, w h ic h a r e  b elieved tob e new  andcom p letely  uns uggested by the a r t. The present  inv e n tio n r e late sto oil and gas  we ll d rillingan d safety va lves use di n oil  and g as wel l drill i n g. More p arti cul arly, the  pr es e nt inve nt io n  relat es t oan imp rovedk elly v alve actuator as sembl y which all ows t he  kellyv alve  to be ope ned or clos ed whe n th e kel ly is s pi nningorst ill from a remote lo catio n.
In t he  oil  an d gaswell d rilli ng i nd ust ry, a pow e r ed ro ta r y t able  rota te s akelly and a kellybus h ing toro tat e the dr i ll s tring at t herig f l o or. Therei s co m mo n ly
1, serine-125_human interleukin-2_from Prometheus Laboratories Inc.,_San Diego_Calif.),_has been_approved_for administration to_patients suffering from_metastatic renal cell carcinoma_and metastatic melanoma._IL-2_has also been suggested for administration in patients suffering from or infected with hepatitis_C_virus (HCV),_human_immunodeficiency_virus (HIV), acute myeloid leukemia,_non-Hodgkin's lymphoma, cutaneous T-cell lymphoma,_juvenile rheumatoid_arthritis, atopic dermatitis, breast cancer and bladder cancer.
Even_recommended_doses of aldesleukin,_however, can cause severe side effects, including capillary leak_syndrome (CLS) and impaired neutrophil function._In view of_the_potential_for these severe side_effects, and because the recommended treatment_cycle involves intravenous infusion over fifteen_minutes every eight hours for fourteen doses,_administration of aldesleukin occurs within a_clinical setting. Moreover, the commercial_formulation of_aldesleukin includes the presence of_sodium dodecyl sulfate,_a substance_that appears to_be required to maintain optimal activity_through conformational stability._See Arakawa et al. (1994) Int._J._Peptide Protein Res._43:583-587.
Attempts_at_addressing the_toxicity concerns of_IL-2_have been_tried._In one approach, formulation approaches have_been_attempted. See, for example, U.S. Pat. No._6,706,289 and international patent_application_publication WO 02/00243 and_WO 99/60128. In other approaches,_certain conjugates of IL-2 have been_suggested. See,_for example,_U.S. Pat. Nos. 4,766,106, 5,206,344, 5,089,261 and 4902,502.
Notwithstanding these approaches, however,_there remains a need for conjugates_of IL-2. Among other_things, one_or_more embodiments of_the_present invention_is therefore directed to such conjugates as_well as_compositions comprising the conjugates and related_methods as described herein,_which_are believed to be new and_completely unsuggested by the art. The_present invention relates to oil_and_gas_well drilling and safety valves_used in oil and gas well_drilling. More particularly,_the present invention relates to an improved_kelly_valve actuator assembly which allows the_kelly_valve to be opened or closed_when_the_kelly is spinning or still_from a remote location.
In the oil_and gas well drilling industry, a powered rotary table_rotates a kelly_and a kelly bushing to_rotate_the_drill string at the rig floor. There is commonly